• BG IRIS Research Client Login
logo
logo
  • Transactions
  • Services
    • Overview
    • Solutions
    • Sector expertise
    • Research
  • Insights
    • Overview
    • White Papers
    • Blog
    • Reports
    • Client Focus
  • About us
    • Overview
    • Senior Team
    • News
    • Events
  • Careers
    • Overview
    • Early careers
    • Experienced hires
    • Employee Growth Stories
  • Media
    • Press
    • Videos
  • Contact
  • Search
  • BG IRIS Research Client Login

Solutions


From raising venture capital to taking companies public, supporting acquisition strategies to advising management buy-outs or finding strategic partners, Bryan Garnier supports clients and their investors at every stage of their growth and investing journeys.​ Bryan Garnier’s holistic approach to advising clients on the full range of equity, debt and M&A transactions creates a true client-first model, building long-term relationships over the full business lifecycle.

M&A Advisory


Private Capital Solutions


Debt Solutions

Public Capital Solutions


Institutional Sales and Trading

Hide filtersShow filters
× Close

Sectors

  • (218)
  • (177)
  • (106)
  • (96)
  • (48)

Deal Type

  • (298)
  • (141)
  • (141)
  • (7)

Clear all Apply

Bryan, Garnier & Co acts as Joint Bookrunner to GenSight on its EUR 25 million Follow-on Offering

Tombstone_gensight

Bryan, Garnier & Co acts as Joint Bookrunner to Targovax on its NOK 75 million Follow-on Offering

Bryan, Garnier & Co acts as Sole Financial Advisor, Sole Global Coordinator and Sole Bookrunner to McPhy on a EUR 180m Follow-on Offering including Strategic Investments from Chart Industries and Technip Energies

McPhy_website_tombstone_4

Bryan, Garnier & Co acts as Joint Bookrunner on Sensorion’s EUR 31 million Follow-on Offering with top tier US and European biotech specialists and institutional investors

website_tombstone_2

Bryan, Garnier & Co acts as European Lead Manager to Humanigen on its USD 78 million Follow-on Offering

tombstone_humanigen_78200000_dollars

Bryan, Garnier & Co acts as Joint Bookrunner to Azelio on its SEK 270 million Follow-on Offering

Azelio tombstone 2

Bryan, Garnier & Co acts as Co-manager to BioNTech on its USD511.5 million upsized Publicly-marketed Follow-on Offering

BioNTech_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Carbios on its EUR 37 million upsized Follow-on Offering

Carbios website tombstone

Bryan, Garnier & Co acts as Sole Global Coordinator on a EUR 7.3 million Rights Issue for medtech company Pixium Vision

Pixium_website_tombstone

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner on MedinCell’s Follow-on with top-tier European biotech specialists and institutional investors

Medincell_website_tombstone

Bryan Garnier & Co acts as Joint Bookrunner and Joint Broker to AIM-listed 4D Pharma on its GBP 22 million equity Fund Raising

4Dpharma_website_tombstone

Bryan, Garnier & Co acts as Sole Bookrunner on GeNeuro EUR17.5 million Private Placement

GeNeuro_website_tombstone
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12

Bryan, Garnier & Co

Bryan Garnier is the world’s leading independent full-service investment bank for European healthcare and technology-led companies and their investors.

CONTACT US
Latest News

  • BCI – Made in France 2025 – Hosted by Bryan, Garnier & Co
  • The Next Launch Window: What It Means for Satcoms
  • BG Growth Series – Avantium
  • Energy-Aware AI: Confronting the power-hungry reality of scaling AI
Quick links

Transactions

Insights

Senior Team

Information

Legal & Regulatory Information

Index 2025

Bryan Garnier Securities

Privacy Policy

Privacy Preference Center

Privacy Preferences

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }